ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,836.60
0.28%
S&P ASX All Technology
3,044.80
-0.01%
Brent Oil
83.595
0.00%
US Dollar vs AUD
1.49325
0.05%
Bitcoin
66,207.92
-0.10%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. 60 Degrees Pharmaceuticals Inc (SXTP)

  7. 60 Degrees Pharmaceuticals Inc (SXTP) News

SXTP

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SXTP
DateTimeSourceHeadlineSymbolCompany
16/05/202403:45GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/05/202421:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/05/202421:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/04/202422:58GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/03/202422:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
21/02/202408:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/02/202423:59GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/02/202423:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/02/202407:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/02/202407:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/02/202404:00PR Newswire (US)WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/02/202403:15GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/01/202401:45PR Newswire (US)WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/01/202401:00GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
23/01/202409:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
22/01/202423:59GlobeNewswire Inc.60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
17/01/202406:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
16/01/202423:59GlobeNewswire Inc.60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
26/12/202323:59GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/11/202323:29GlobeNewswire Inc.60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/10/202323:31GlobeNewswire Inc.60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in BostonNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
13/10/202307:16GlobeNewswire Inc.60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/09/202306:16GlobeNewswire Inc.60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/09/202321:31GlobeNewswire Inc.60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/08/202321:32GlobeNewswire Inc.60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal ActivityNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
22/08/202321:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum MalariaNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/08/202321:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.govNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/07/202321:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive SubjectsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/07/202303:30PR Newswire (US)WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per UnitNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTP

Your Recent History

AMEX
IBDY
ishares ibonds Dec 2033 ...
BIT
F24466
Vontobel Financial Produ...
LSE
GBDV
Spdr Glob Div
USOTC
ALTUF
Altus Strategies (QX)
USOTC
RSCVS
RSE Archive (GM)
USOTC
RDWWF
Redrow (PK)
EU
MLCMG
CMG Clean Tech
USOTC
COFI
Credit One Financial (CE)
TG
T2G
Tradegate Ag O N
USOTC
RHEPB
Regional Health Properties (QB)
TG
STS1
Santos
USOTC
RBLOS
RSE Archive (GM)
BIT
F30018
Vontobel Financial Produ...
KOSPI
047810
Korea Aerospace Industries
ASX
DCGPA
Decmil
EU
V222S
V222S
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved